Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma

被引:18
作者
Jin, Bo [1 ]
Dong, Yu [1 ]
Wang, Hui-min [1 ]
Huang, Jin-su [1 ]
Han, Bao-hui [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm, Shanghai 200030, Peoples R China
关键词
lung cancer; adenocarcinoma; biomarker; carcinoembryonic antigen; EGFR; mutation; exon; 19; deletion; nonsmoker; CARCINOEMBRYONIC ANTIGEN LEVEL; PREVIOUSLY TREATED PATIENTS; FACTOR RECEPTOR MUTATIONS; TUMOR-MARKERS; PROGNOSTIC-FACTORS; CANCER; GEFITINIB; CYFRA-21-1; GROWTH; CHEMOTHERAPY;
D O I
10.1038/aps.2013.164
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Aim: To evaluate the relationship between epidermal growth factor receptor (EGFR) mutations and serum carcinoembryonic antigen (CEA) levels in Chinese nonsmokers with pulmonary adenocarcinoma. Methods: We sequenced exons 18-21 of the EGFR gene in 98 cases. The patients were divided into two groups based on their pretreatment serum CEA levels (below or above 5 ng/mL) for analyzing the correlations with EGFR mutations. Results: Sixty-seven cases harbored EGFR mutations. The rates of EGFR mutations and exon 19 mutations in the high-CEA group (78.2% and 49.1%, respectively) were significantly higher than those in the low-CEA group (55.8% and 20.9%, respectively). Serum CEA levels were found to be the only independent predictor of EGFR mutation (OR 2.837; 95% CI: 1.178-6.829) and exon 19 mutation (OR 3.618; 95% CI: 1.319-9.918). Furthermore, a higher serum CEA level was associated with a higher EGFR mutation rate and a higher exon 19 mutation rate: patients with serum CEA levels <5 ng/mL, >= 5 and >20 ng/mL, >= 20 ng/mL showed the EGFR mutation rate of 55.8%, 74.1%, 82.1%, respectively, and the exon 19 mutation rate of 20.9%, 40.7%, 57.1%, respectively. Patients with EGFR mutations displayed a significantly higher incidence of abnormal serum CEA levels (>5 ng/mL) than patients without EGFR mutations (64.2% vs 38.7%). Conclusion: Elevated serum CEA levels predict the presence of EGFR gene mutations in Chinese nonsmokers with pulmonary adenocarcinoma.
引用
收藏
页码:373 / 380
页数:8
相关论文
共 31 条
[1]   Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer [J].
Barlési, F ;
Gimenez, C ;
Torre, JP ;
Doddoli, C ;
Mancini, J ;
Greillier, L ;
Roux, F ;
Kleisbauer, JP .
RESPIRATORY MEDICINE, 2004, 98 (04) :357-362
[2]   Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].
Fukuoka, M ;
Yano, S ;
Giaccone, G ;
Tamura, T ;
Nakagawa, K ;
Douillard, JY ;
Nishiwaki, Y ;
Vansteenkiste, J ;
Kudoh, S ;
Rischin, D ;
Eek, R ;
Horai, T ;
Noda, K ;
Takata, I ;
Smit, E ;
Averbuch, S ;
Macleod, A ;
Feyereislova, A ;
Dong, RP ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246
[3]   DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES [J].
GOLD, P ;
FREEDMAN, SO .
JOURNAL OF EXPERIMENTAL MEDICINE, 1965, 121 (03) :439-+
[4]   First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy [J].
Inoue, Akira ;
Kobayashi, Kunihiko ;
Usui, Kazuhiro ;
Maemondo, Makoto ;
Okinaga, Shoji ;
Mikami, Iwao ;
Ando, Masahiro ;
Yamazaki, Koichi ;
Saijo, Yasuo ;
Gemma, Akihiko ;
Miyazawa, Hitoshi ;
Tanaka, Tomoaki ;
Ikebuchi, Kenji ;
Nukiwa, Toshihiro ;
Morita, Satoshi ;
Hagiwara, Koichi .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1394-1400
[5]  
Ishiguro F, 2010, ANN THORAC CARDIOVAS, V16, P242
[6]   The Value of Tumor Markers in Evaluating Chemotherapy Response and Prognosis in Chinese Patients with Advanced Non-Small Cell Lung Cancer [J].
Jin, Bo ;
Huang, Ai-mi ;
Zhong, Run-bo ;
Han, Bao-hui .
CHEMOTHERAPY, 2010, 56 (06) :417-423
[7]   Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib [J].
Jung, Minkyu ;
Kim, Se Hyun ;
Lee, Young Joo ;
Hong, Soojung ;
Kang, Young Ae ;
Kim, Se Kyu ;
Chang, Joon ;
Rha, Sun Young ;
Kim, Joo Hang ;
Kim, Dae Joon ;
Cho, Byoung Chul .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2011, 2 (04) :685-693
[8]   Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment [J].
Kappers, I. ;
Vollebergh, M. A. ;
van Tinteren, H. ;
Korse, C. M. ;
Nieuwenhuis, L. L. ;
Bonfrer, J. M. G. ;
Klomp, H. M. ;
van Zandwijk, N. ;
van den Heuvel, M. M. .
ECANCERMEDICALSCIENCE, 2010, 4
[9]  
Kasimir-Bauer S, 2003, ONCOL REP, V10, P475
[10]   Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial [J].
Kim, Edward S. ;
Hirsh, Vera ;
Mok, Tony ;
Socinski, Mark A. ;
Gervais, Radj ;
Wu, Yi-Long ;
Li, Long-Yun ;
Watkins, Claire L. ;
Sellers, Mark V. ;
Lowe, Elizabeth S. ;
Sun, Yan ;
Liao, Mei-Lin ;
Osterlind, Kell ;
Reck, Martin ;
Armour, Alison A. ;
Shepherd, Frances A. ;
Lippman, Scott M. ;
Douillard, Jean-Yves .
LANCET, 2008, 372 (9652) :1809-1818